
My team is in the zone! More good news to report. Just completed our latest patent application: BiTides™, linked peptides that target different checkpoint receptors or double-down on one. Data is exciting; potency dramatically increased. This is the fourth class of immune modulating peptides we’ve filed on. Two more on track for this year.


